Paul Stoffels, Johnson & Johnson Vice Chairman and CSO, to retire Dec 31, 2021

JOHNSON & JOHNSON

Paul Stoffels, Vice Chairman and Chief Scientific Officer, will retire effective December 31, 2021.
Stoffels led J&J's R&D pipeline, including development of over 25 new medicines and the COVID-19 vaccine.
Joaquin Duato, current Vice Chairman, is set to become CEO on January 3, 2022; transition for R&D teams is planned.
Stoffels established Johnson & Johnson Innovation and JLABS network with over 700 incubating companies.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Paul Stoffels

Vice Chairman of the Executive Committee and Chief Scientific Officer

JNJ · JOHNSON & JOHNSON

Effective: 2021-12-31
Filed: October 12, 2021, 7:59 PM ET

On October 12, 2021, Johnson & Johnson (the “Company”) issued a press release announcing that Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, has elected to retire, effective December 31, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Stoffels retired as Vice Chairman of the Executive Committee and Chief Scientific Officer at JOHNSON & JOHNSON.

Action: retired
Role: Vice Chairman of the Executive Committee and Chief Scientific Officer

Exact text from the filing

On October 12, 2021, Johnson & Johnson (the “Company”) issued a press release announcing that Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, has elected to retire, effective December 31, 2021.

View on SEC.gov

JOHNSON & JOHNSON filing history →

Source: SEC EDGAR

accession 0000200406-21-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.